Clinical trials
Lung Cancer Stage III clinical trials
Below are recruiting lung cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 386 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06467786RecruitingPhase 4
Irinotecan liposomes for advanced small cell lung cancer
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
Xi'an, ShannxiAges 18 years+ - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07227623Recruiting
Digital health program to help lung cancer survivors get active
This trial tests a digital health tool to help lung cancer patients improve their physical function and wellness during and after treatment. It is designed for people with early-stage lung cancer who are starting treatment with chemotherapy, immunotherapy, or radiation.
Boston, MassachusettsAges 18 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
New Haven, ConnecticutAges 18 years+ - NCT05651594RecruitingPhase 2
Propranolol with pembrolizumab and chemotherapy for esophageal cancer
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT07082179RecruitingPhase 2
Immunotherapy plus chemotherapy for stage III lung cancer
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
NanjingAges 18–75 - NCT05011487RecruitingPhase 2
Before-surgery osimertinib plus chemotherapy for EGFR lung cancer
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
Guangzhou, GuangdongAges 18–75 - NCT07131319RecruitingPhase 2/Phase 3
Combination therapy for advanced lung cancer
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Nanchang, JiangxiAges 18–85 - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT06332274RecruitingPhase 3
Tislelizumab for cancer patients with minimal residual disease
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
Villejuif, Val De MarneAges 18 years+ - NCT07306624RecruitingPhase 2
Nelmastobart plus docetaxel for advanced lung cancer
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Gyeonggi-doAges 19 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT06038227Recruiting
Robotic vs. VATS surgery for early lung cancer
This study compares two types of minimally invasive surgery—robotic-assisted (da Vinci) and VATS—for people with early-stage non-small cell lung cancer. The goal is to see which approach might work better and help patients recover faster.
CopenhagenAges 18 years+ - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT06692972Recruiting
How lung cancer tumors change after high-dose radiation
This study looks at how the main lung tumor shrinks or changes after a complete course of high-dose radiation in people with stage II or III lung cancer. It uses scans taken before and after treatment to track the results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT03851445RecruitingPhase 2/Phase 3
Lung cancer screening trial using tumor and blood test results
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
Birmingham, AlabamaAges 18 years+ - NCT06137378RecruitingPhase 2
Pembrolizumab for advanced throat cancer to avoid laryngectomy
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
Mannheim, Baden-WürtembergAges 18–70 - NCT06810609RecruitingPhase 2
Immunochemotherapy, surgery, and durvalumab for stage III lung cancer
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
Freiburg im Breisgau, Baden-WurttembergAges 18–74 - NCT05211895RecruitingPhase 3
Durvalumab plus domvanalimab after chemoradiation for stage 3 lung cancer
This trial studies whether adding durvalumab and domvanalimab after standard chemoradiation can keep unresectable stage 3 lung cancer from coming back or getting worse. It targets tumors with specific lab test results (including PD-L1 and gene markers).
Chandler, ArizonaAges 18 years+ - NCT06424899RecruitingPhase 2
Chemoimmunotherapy before and after chemoradiation for stage III lung cancer
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT07609121RecruitingPhase 2
Radiation, Chemotherapy, and Immunotherapy for Advanced Lung Cancer
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75
Hear when a new Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage iii?
- Yes. Clin2 currently lists 386 recruiting lung cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non-small Cell Lung Cancer Stage III
- Stage III Lung Cancer AJCC v8
- Nonsmall Cell Lung Cancer Stage III
- Unresectable Stage III Non-small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Stage IV Lung Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.